The company’s trial of Haduvio met its primary and secondary endpoints in reducing coughing fits across patients by 53%.

A new batch of neflamapimod capsules led to increased plasma drug concentrations and demonstrated improvement (p<0.001 vs. old capsules; p=0.003 vs. placebo) on the primary outcome measure, change ...

Phase 3 AURORA trial of Descartes-08 in myasthenia gravis on track to commence in 1H25; Deep and durable responses maintained over 12 months in ...

CervoMed has announced positive results from the extension phase 2b RewinD-LB study of neflamapimod for dementia with Lewy ...

Protagonist Therapeutics (PTGX) announced topline results from ANTHEM-UC, a Phase 2b study of icotrokinra, the first investigational targeted ...

The company’s Phase IIb trial found the therapy, N6LS, was able to maintain viral loads below a detectable threshold.

Hudson Therapeutics, the U.S. subsidiary of Shaperon, announced today that Shaperon will commence the Phase 2b Part 2 of its ...

Pliant Therapeutics discontinues Phase 2b trial of bexotegrast for idiopathic pulmonary fibrosis due to safety concerns, but ...

Completing the $7.2 billion buyout of AspenTech "marks a key milestone in the final phase of Emerson's portfolio ...

Investing.com -- Shares of Lexicon Pharmaceuticals , Inc. (NASDAQ: LXRX) tumbled 55% after the company announced topline results from its PROGRESS Phase 2b study, which evaluated pilavapadin in ...

The completed campus near Salt Lake City will have more than 1 million sq ft of data centers with a combined 175-MW capacity.

The Phase 2b pre-specified analyses of subgroups showed that in patients with occult and minimally classic lesions excluding RAP, which represented 73% of the Phase 2b total patient population ...